PI3K (alpelisib) and mTOR (everolimus) inhibitors, which have FDA approval, provide more treatment options for advanced BC patients with HR-positive and HER2-negative status after progression on endocrine therapy; they have shown better ORR rates in TNBC clinical trials. Here, ERBB2 is linked to breast cancer.